Scientific Posters PBI-4050

Fezagepras (PBI-4050) Reduces Pulmonary Fibroblast Activation

Fezagepras (PBI-4050) reduces angio-proliferative pulmonary arterial hypertension

Fezagepras (PBI-4050) reverses metabolic dysregulation induced by a high fat diet

PBI-4050 promotes hepatic stellate cell autophagymitophagy and restores a quiescent-like phenotype

PBI-4050 Reduces Renal Injury in a Mouse Model of Aristolochic Acid-Induced Nephropathy

PBI-4050 Reduces Systemic Inflammation, Electrolyte Disturbances and Renal Injury in Mice with Sepsis-induced Acute Kidney Injury; Role of G

PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

PBI-4050 reduces systemic inflammation, electrolyte disturbances and renal injury in mice with sepsis-induced acute kidney injury

PBI-4050 exerts anti-inflammatory and anti-fibrotic effects in several diabetic and non-diabetic models of kidney injury through modulation of GPR40 and GPR84 fatty acid receptors.

PBI-4050 decreases adenine-induced tubulointerstitial injury and er-stress; implications of the GPR40 receptor

The aim of this study was to further examine the effects of PBI-4050 in both WT and GPR40 activation-/- mice on adenine-induced tubulointerstitial injury, anemia and the unfolded protein response path

PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

These results suggest that PBI-4050 is a strong potential candidate for the treatment of metabolic diseases and related diabetic nephropathy.